Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non–Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study Clinical trials frequently include multiple end points that ...
Please provide your email address to receive an email when new articles are posted on . Pembrolizumab added to twice weekly gemcitabine plus transurethral muscle-invasive urothelial cancer resection ...
Anti-programmed death-1 inhibitors and nimotuzumab in combination with induction chemotherapy for locoregionally advanced nasopharyngeal carcinoma: A propensity score-matched analysis. This is an ASCO ...
Please provide your email address to receive an email when new articles are posted on . First phase 3 study to show a survival benefit with adjuvant therapy in kidney cancer. Adjuvant pembrolizumab ...
Merck & Co (MSD) and Adcendo have entered a collaboration and supply agreement to evaluate ADCE-T02 with Keytruda ...
BioInvent International (STO:BINV)24% confirmed ORR (including complete response) in heavily pretreated patients (n=25) with advanced ovarian cancer who received BI-1808 and KEYTRUDA - multiplying by ...
This is the first positive Phase 3 trial for WELIREG in earlier-stage disease, the first positive results for a HIF-2α inhibitor and immunotherapy combination and the first study in earlier-stage ...
A combination of belzutifan, pembrolizumab, and lenvatinib showed encouraging results as first-line treatment for advanced RCC in an early phase trial. Phase 3 trial data are pending. Among first-line ...
Patients for whom cisplatin-based therapy is unsuitable live significantly longer with the new drug combination than with previous therapy options. Institute for Quality and Efficiency in Health Care ...
The US Food and Drug Administration (FDA) has approved the checkpoint inhibitor pembrolizumab (Keytruda, Merck) alongside standard chemotherapy — with or without bevacizumab — as first-line therapy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results